Lytix Biopharma is a private clinical-stage biotech company developing proprietary oncolytic peptides as a novel immune therapy to fight cancer. Lead compound LTX-315 turns cold tumors hot providing access to antigens and tumor infiltrating lymphocytes (TILs) using the patient’s own tumor as source.

 

Local treatment with LTX-315 targets the first step in the cancer immunity cycle with a potential cornerstone position in immunotherapy.